Dr. Kalali is recognized globally as a leading innovator at the intersection of life sciences and technology. At Signant he helps identify innovative technologies and methodologies to support Signant’s growth, and clients navigate the evolving landscape.
Dr. Kalali was the Founding Chairman of the Executive Committee of the International Society for CNS Drug Development (ISCDD), and a founding member of the International Society for CNS Clinical Trials and Methodology (ISCTM). He is also a founder and Chairman of the CNS Summit.
He is Professor of Psychiatry at University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development, published by Cambridge University Press. He has authored over 250 peer-reviewed publications.